Moreover, bispecific antibodies (BsAbs) that can simultaneously block TIM-3 and PD-1 are also explored in ongoing trials involving NSCLC patients [NCT03708328 (182, 185); NCT04931654 (186)]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.